$MBRX News

Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting

Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate

Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding

Moleculin Announces Data From Phase 2B/3 "MIRACLE" Trial Evaluating Annamycin In Combination With Cytarabine

Moleculin Biotech Announces Publication Of An Abstract At The European Hematology Association Congress That Highlights The Cardiac Safety Profile Of Annamycin

Moleculin Biotech Announces Significant Advancement In IP Portfolio With Issuance Of Hong Kong Patent Covering Proprietary Method Of Reconstituting Liposomal Annamycin

HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target

Moleculin Biotech Announces 45th Enrollee In Phase2B/3 Trial For Annamycin Plus Cytarabine As A Treatment For Relapsed Or Refractory Acute Myeloid Leukemia

Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate

Moleculin Biotech Confirms 45-Patient Interim Data Unblinding In Pivotal MIRACLE Trial On Track For Mid-2026

Moleculin Biotech Confirms 45-Patient Interim Data Unblinding In Pivotal MIRACLE Trial On Track For Mid-2026

12 Health Care Stocks Moving In Thursday's Intraday Session

Moleculin Biotech shares are trading higher after the company announced it is approaching the first unblinding of data in its pivotal Phase 2B/3 "MIRACLE" study of Annamycin in combination with cytarabine in AML treatment.

Moleculin Biotech Reports Preliminary Composite Complete Remission Rate Of 40% In Phase 2B/3 Miracle Trial's First 30 Subjects Treated, With Annamycin In Combination With Cytarabine For Refractory To Or Relapsed Acute Myeloid Leukemia After Induction Therapy

Moleculin Biotech Secures Japan Patent Allowance For Liposomal Annamycin Method

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

Moleculin Biotech Receives New Independent Assessment For Absence Of Cardiotoxicity In Annamycin, 90 Subjects Reviewed To Date

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

Moleculin Biotech Provides Business Outlook, Outlines Expected Upcoming Milestones For Next Gen Non-Cardiotoxic Anthracycline Annamycin And STAT3 Inhibitor WP1066; First MIRACLE Trial Unblinding Expected Q1 2026

Moleculin Biotech Regains Nasdaq Listing Compliance; Delisting Hearing Canceled